Latest News on RCKT

Financial News Based On Company


Advertisement
Advertisement

RCKT: Rocket Pharmaceuticals officer proposes sale of 2,216 shares

https://www.quantisnow.com/insight/sec-form-144-filed-by-rocket-pharmaceuticals-inc-6798584
Gaurav Shah, a director and officer at Rocket Pharmaceuticals (RCKT), plans to sell 2,216 shares worth $4,828 on November 18, 2026. This sale is primarily to cover a tax obligation arising from vested restricted stock. The amount of shares proposed for sale is relatively small compared to the company's total outstanding shares.

A proposed sale of 2,216 Rocket Pharmaceuticals (RCKT) shares includes an amount to cover taxes.

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-29e452035cf6.html
Rocket Pharmaceuticals (RCKT) officer and director, Gaurav Shah, has filed notice of a proposed sale of 2,216 common shares with an approximate market value of $4,827.56, scheduled for November 18, 2026. The sale is intended to cover a tax obligation from a vested equity award distribution. Shah previously sold 2,293 common shares on August 18, 2026, and 3,020 common shares on November 13, 2026.

Rocket Pharmaceuticals general counsel sells $9,195 in shares By Investing.com

https://in.investing.com/news/stock-market-news/rocket-pharmaceuticals-general-counsel-sells-9195-in-shares-93CH-5711860
Martin Wilson, General Counsel at Rocket Pharmaceuticals (NASDAQ:RCKT), sold 4,087 shares for $9,195 to cover tax withholding obligations. This sale comes as the stock trades near its 52-week low. Despite the recent decline, InvestingPro analysis indicates the stock may be undervalued, and the company has shown significant progress in its RP-A501 program, leading to various analyst rating changes.

Form 4 Rocket Pharmaceuticals Inc: Martin Wilson (General Counsel) For: 13 November

https://uk.investing.com/news/stock-market-news/form-4-rocket-pharmaceuticals-inc-martin-wilson-general-counsel-for-13-november-93CH-4989896
The article reports on a Form 4 filing for Rocket Pharmaceuticals Inc, detailing an insider transaction by Martin Wilson, the General Counsel, on November 13. This brief announcement, published on November 18, 2026, highlights a specific disclosure of corporate stock ownership changes. No further details about the nature of the transaction are provided in the snippet.

Chardan Capital maintains Rocket Pharmaceuticals at Buy, keeps price target at $11

https://www.tradingview.com/news/tradingview:86001687d8aed:0-chardan-capital-maintains-rocket-pharmaceuticals-at-buy-keeps-price-target-at-11/
Chardan Capital has reiterated its 'Buy' rating for Rocket Pharmaceuticals (RCKT) and maintained its price target at $11. This price target suggests a potential upside of 409.3% from the stock's closing price of $2.16 on November 16. The report encourages investors to explore more detailed price target data and analyst recommendations.
Advertisement

Form 144 ROCKET PHARMACEUTICALS For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-rocket-pharmaceuticals-for-14-november-93CH-4958479
This article announces the filing of Form 144 for Rocket Pharmaceuticals (RCKT) on November 14, 2026. Form 144 indicates an intent to sell restricted or control securities. The article provides the title and date of the filing and mentions RCKT's stock performance.

Martin Wilson proposes selling 4,087 Rocket Pharmaceuticals (RCKT) shares after stock vesting.

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-b8bc4af8aa42.html
Martin Wilson, an officer at Rocket Pharmaceuticals, has proposed selling 4,087 common shares of RCKT, valued at approximately $9,196.98, with an approximate sale date of November 13, 2026. These shares were acquired on November 11, 2026, through restricted stock vesting as compensation, and the proposed sale includes an amount to cover tax obligations from this equity award distribution. The SEC filing provides details on the current proposed sale and lists several earlier sales made by Wilson between August and November 2026.

Gaurav Shah proposes selling 3,020 shares of Rocket Pharmaceuticals (RCKT).

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-62e861874217.html
Gaurav Shah, an officer and director of Rocket Pharmaceuticals (RCKT), has proposed selling 3,020 common shares valued at $6,795.91, with an approximate sale date of November 13, 2026. These shares were acquired through restricted stock vesting on November 11, 2026, as compensation, and the sale includes an amount to cover tax obligations from a vested equity award distribution. Shah also had prior sales of 2,837 shares on August 13, 2026, and 2,293 shares on August 18, 2026.

Form 4 Rocket Pharmaceuticals Inc: Sarbani Chaudhuri (Officer) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-rocket-pharmaceuticals-inc-sarbani-chaudhuri-officer-for-9-november-93CH-5701465
This article reports on a Form 4 filing for Rocket Pharmaceuticals Inc, indicating an insider transaction by Sarbani Chaudhuri, an officer of the company, on November 9th. The filing is a standard disclosure requirement by the SEC for significant changes in ownership of company stock by insiders. The article also notes Rocket Pharmaceuticals' stock symbol, RCKT, and its recent price performance.

Form 4 Rocket Pharmaceuticals Inc: Sarbani Chaudhuri (Officer) For: 9 November

https://uk.investing.com/news/stock-market-news/form-4-rocket-pharmaceuticals-inc-sarbani-chaudhuri-officer-for-9-november-93CH-4979355
The article reports that Sarbani Chaudhuri, an officer at Rocket Pharmaceuticals Inc. (RCKT), filed a Form 4 on November 9th. This filing indicates a change in beneficial ownership of the company's stock by an insider. The news was published on November 13, 2026, by Investing.com.
Advertisement

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

https://www.quantisnow.com/insight/rocket-pharmaceuticals-reports-third-quarter-2026-financial-results-and-highlights-6787450
Rocket Pharmaceuticals reported a Q3 2026 net loss of $49.2 million ($0.43/share), an improvement from $50.3 million a year prior, primarily due to reduced R&D expenses. The company also announced FDA alignment for the pivotal Phase 2 trial of RP-A501 in Danon disease, with dosing completion anticipated by mid-2027. A new Hercules credit facility provides additional liquidity, extending their cash runway into Q3 2028, though further borrowings are conditional on milestones.

Form 144 ROCKET PHARMACEUTICALS For: 10 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-rocket-pharmaceuticals-for-10-november-93CH-4945525
This article from Investing.com announces a Form 144 filing for ROCKET PHARMACEUTICALS on November 10. Form 144 is a notice of the intent to sell restricted securities, typically filed by company insiders. The article provides minimal details beyond the filing announcement.

A proposed 16,131-share sale at Rocket Pharmaceuticals (RCKT) includes shares to cover taxes.

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-90ffc42b5ef2.html
Rocket Pharmaceuticals officer Christopher James Stevens has proposed selling 16,131 common shares, valued at approximately $37,530.38, around November 9, 2026. This sale primarily aims to cover a tax obligation resulting from the settlement of a vested equity award distribution. Stevens also sold 36,658 common shares on August 11, 2026, generating gross proceeds of $128,281.01.

An officer proposes selling 4,872 Rocket Pharmaceuticals (RCKT) shares after stock vesting.

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-d2aed03fc18c.html
Rocket Pharmaceuticals (RCKT) officer Sarbani Chaudhuri is proposing to sell 4,872 common shares, valued at $11,335.20, following the vesting of restricted stock. This sale, planned for approximately November 9, 2026, also includes an amount to cover tax obligations from the vested equity award distribution. The filing also notes a previous sale of 4,701 shares on August 11, 2026, for $16,450.68.

Rocket Pharmaceuticals Inc (9IP1.DU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/9IP1.DU/seasonality/
This article from Yahoo Finance presents a seasonality chart for Rocket Pharmaceuticals Inc (9IP1.DU), displaying the average monthly price return for the period between 2021 and 2026. The stock closed at 2.1400 EUR, down 4.04% on October 30 at 19:30:16 CET.
Advertisement

Vanguard reports a passive stake in Rocket Pharmaceuticals (RCKT) spanning funds and clients.

https://www.stocktitan.net/sec-filings/RCKT/schedule-13g-a-rocket-pharmaceuticals-inc-amended-passive-investment--1f4d46d81989.html
Vanguard Portfolio Management has reported a beneficial ownership of 1,463,677 shares, representing 1.33% of Rocket Pharmaceuticals, Inc. (RCKT) as of September 30, 2026. This stake includes securities held by various Vanguard affiliates and funds, with Vanguard exercising sole voting power over 37,351 shares and sole dispositive power over all 1,463,677 shares. The filing, a SCHEDULE 13G/A, indicates a passive investment.

Rocket Pharmaceuticals, Inc. (RCKT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/RCKT/seasonality/
This article from Yahoo Finance presents the seasonal returns chart for Rocket Pharmaceuticals, Inc. (RCKT). It displays the average monthly price return for the company's stock from 2016 to 2026, offering insights into its historical seasonality. The page also includes current stock performance data and links to related financial information for RCKT.

3 Promising Penny Stocks With Market Caps Under $800M

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rckt/rocket-pharmaceuticals/news/3-promising-penny-stocks-with-market-caps-under-800m-2/amp
This article identifies three promising "penny stocks" with market caps under $800M: Rocket Pharmaceuticals (RCKT), UP Fintech Holding (TIGR), and Valens Semiconductor (VLN). It highlights their financial resilience and growth potential, despite being smaller or less-established companies. Each stock is assessed for its financial health, recent developments, and market position.

Rocket Pharmaceuticals, Inc. Estimates – NASDAQ:RCKT

https://www.tradingview.com/symbols/NASDAQ-RCKT/financials-estimates/
This page on TradingView provides financial data and analyst estimates for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time across income statements, balance sheets, cash flow statements, and valuation metrics. The platform offers both annual and quarterly data for comprehensive financial analysis.

Rocket Pharmaceuticals, Inc. Estimates – BOATS:RCKT

https://www.tradingview.com/symbols/BOATS-RCKT/financials-estimates/
This article provides an overview of Rocket Pharmaceuticals, Inc. (RCKT) financial estimates on TradingView, covering reported financial data and analyst estimates across various statements and valuation metrics. It allows users to compare actual results with average, high, and low estimates, and visualize trends over time. The platform also includes a disclaimer stating that the information is not investment advice.
Advertisement

Rocket Pharmaceuticals, Inc. Estimates – HAN:9IP1

https://www.tradingview.com/symbols/HAN-9IP1/financials-estimates/
This article provides an overview of Rocket Pharmaceuticals, Inc. (9IP1) on the Hannover Stock Exchange, focusing on its financial data and analyst estimates. Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.

Rocket Pharmaceuticals schedules November 5 results for Rocket Pharmaceuticals stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rocket-pharmaceuticals-schedules-november-5-results-for-rocket-pharmaceuticals-stock/70378290
Rocket Pharmaceuticals (RCKT) is scheduled to report its next financial results on November 5, 2026. As of June 30, 2026, the company had cash, cash equivalents, and investments totaling USD 283.70 million, with additional funding secured through a Hercules Capital credit facility to extend its cash runway into Q3 2028. Investors will focus on cash usage, adjusted earnings, and development spending in the upcoming report, especially given the company's stock is trading near its 52-week low.

Rocket Pharmaceuticals stock fell 7.63 percent to USD 2.18, 0.46 percent above yearly low

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rocket-pharmaceuticals-stock-fell-7-63-percent-to-usd-2-18-0-46-percent-above-yearly-low/70349328
Rocket Pharmaceuticals (RCKT) stock declined by 7.63% to USD 2.18 on October 16, 2026, placing it just above its 52-week low. This drop follows Leerink Partners cutting its price target for RCKT from USD 7.00 to USD 4.00 earlier in October. The company, which develops gene therapies for rare diseases, is currently valued at a market capitalization of USD 239.3 million with a trailing P/E ratio of -12.82.

Rocket Pharmaceuticals stock fell 7.63 percent to USD 2.18, 0.46 percent above yearly low

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rocket-pharmaceuticals-stock-fell-7-63-percent-to-usd-2-18-0-46-percent/70349328
Rocket Pharmaceuticals (RCKT) stock declined by 7.63% to $2.18 on October 16, 2026, placing it just $0.01 above its 52-week low. This drop follows Leerink Partners cutting its price target for the company from $7.00 to $4.00 earlier in October. The gene therapy company, focusing on rare and severe diseases, now faces renewed scrutiny regarding its valuation and clinical pipeline, with a market capitalization of $239.3 million.

Goldman Sachs raises target to USD 4.00 for Rocket Pharmaceuticals stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/goldman-sachs-raises-target-to-usd-4-00-for-rocket-pharmaceuticals-stock/70333422
Goldman Sachs has raised its price target for Rocket Pharmaceuticals (RCKT) stock to USD 4.00 from USD 3.00, also upgrading its rating from Sell to Neutral. This new target is still significantly below the consensus target of USD 7.77 set by twelve analysts. Rocket Pharmaceuticals, a loss-making biotechnology company, was trading at EUR 2.10 with a market capitalization of USD 259.1 million as of October 15, 2026.
Advertisement

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

https://finance.yahoo.com/healthcare/articles/rocket-pharmaceuticals-participate-chardan-10th-110000833.html
Rocket Pharmaceuticals (NASDAQ: RCKT) will participate in Chardan's 10th Annual Healthcare Conference, including a panel discussion and investor meetings on Tuesday, October 20, 2026, at 11:30 AM ET. The company is a commercial-stage biotechnology firm focused on developing genetic medicines for rare and life-threatening diseases, particularly inherited cardiovascular disorders. Rocket Pharmaceuticals also issued a cautionary statement regarding forward-looking statements, highlighting various risks associated with clinical trials, regulatory approvals, manufacturing, and financial requirements.

Rocket receives $150m credit facility to advance cardiovascular portfolio

https://www.pharmaceutical-technology.com/news/rocket-150m-advance-cardiovascular-portfolio/
Rocket Pharmaceuticals secured a credit facility of up to $150 million from Hercules Capital to fund its cardiovascular pipeline, particularly the pivotal Phase II trial for RP-A501 in Danon disease. This financing, combined with existing reserves, is expected to extend the company's operational cash runway into the third quarter of 2028, with potential further extensions into 2029. The agreement includes an initial $35 million drawdown, with additional tranches tied to contractual terms and clinical milestones.

Rocket Pharmaceuticals Raised to Neutral From Sell by Goldman Sachs

https://www.moomoo.com/news/post/1000757859/rocket-pharmaceuticals-raised-to-neutral-from-sell-by-goldman-sachs
Goldman Sachs has upgraded its rating for Rocket Pharmaceuticals from "Sell" to "Neutral." This indicates a change in the firm's outlook on the company's stock, suggesting a more balanced or less negative view of its future performance.

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

https://www.stocktitan.net/overview/RCKT/
Rocket Pharmaceuticals (RCKT) is a late-stage biotechnology company focused on developing genetic therapies for rare cardiovascular and hematologic disorders. The company has prioritized its AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM) and regulatory activities for KRESLADI in severe LAD-I, while pausing internal investment in other programs like Fanconi Anemia and Pyruvate Kinase Deficiency. Recent news includes FDA alignment on a pivotal Phase 2 trial for RP-A501 and a $35M loan deal, with its stock experiencing a -30.2% change over the last year.

Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral From Sell, Price Target is $4

https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-upgrades-rocket-pharmaceuticals-111717227.html
Goldman Sachs has upgraded Rocket Pharmaceuticals (RCKT) from Sell to Neutral, setting a new price target of $4. Despite this upgrade, the company's average analyst rating remains overweight with a mean price target of $8.58.
Advertisement

Rocket Pharmaceuticals Secures Up to $150 Million Hercules-Backed Term Loan With Multi-Tranche Structure

https://www.tradingview.com/news/tradingview:651adf74e2402:0-rocket-pharmaceuticals-secures-up-to-150-million-hercules-backed-term-loan-with-multi-tranche-structure/
Rocket Pharmaceuticals has secured a senior secured term loan facility of up to $150 million from Hercules Capital, structured across five tranches with immediate and milestone-based access to funds. The agreement includes an initial $35 million draw, flexible interest-only periods, and maturity in 2030, with a possible extension to 2031. In connection with the financing, Rocket issued lender warrants for up to 1,755,853 shares at $2.99, aiming to enhance liquidity for advancing its pipeline, notably RP-A501 for Danon Disease.

Rocket Pharma Sets 2028 BLA Goal for Danon Disease Gene Therapy

https://www.genomeweb.com/business-news/regulatory/gnw-rocket-danon-gene-therapy-pivotal-trial-20261007/
Rocket Pharma aims to submit a Biologics License Application (BLA) to the FDA for its Danon disease gene therapy by 2028. The company is actively developing this gene therapy to address the rare genetic disorder. This target BLA filing date signifies a key milestone in Rocket Pharma's development pipeline.

Rocket Pharmaceuticals' price target cut to $2.95 amid gene therapy progress and new funding.

https://pluang.com/en/news-feed/penurunan-target-harga-rocket-pharmaceuticals
Jefferies analyst Andrew Tsai has lowered Rocket Pharmaceuticals' price target to $2.95, while its shares currently trade at $2.48. The company is advancing its gene therapy RP-A501 for Danon disease and recently secured $35 million in funding, extending its cash runway into Q3 2028. This funding supports the development of treatments for rare diseases, though specific trial results have not yet been released.

Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility

https://www.proactiveinvestors.com/companies/news/1099754/rocket-pharmaceuticals-shares-rise-4-after-securing-access-to-150-million-credit-facility-1099754.html
Rocket Pharmaceuticals (NASDAQ: RCKT) saw its shares increase by 4% after securing access to a $150 million credit facility from Hercules Capital. This funding will support its pivotal Phase 2 study of RP-A501 for Danon disease and its broader cardiovascular pipeline. The company also provided an update on the trial, noting positive early safety observations from the first three patients treated under a modified protocol, and expects to complete pivotal trial dosing by mid-2027 with topline results in mid-2028.

Rocket Pharma outlines path for Danon disease gene therapy

https://www.investing.com/news/company-news/rocket-pharma-outlines-path-for-danon-disease-gene-therapy-93CH-4936868
Rocket Pharmaceuticals Inc. announced details from its Danon disease gene therapy program, including a pivotal Phase 2 trial involving 12 male patients receiving RP-A501 at a recalibrated dose. The trial aims for accelerated approval, with success requiring myocardial LAMP2 protein expression and a reduction in left ventricular mass index. The company anticipates completing pivotal trial dosing by mid-2027 and releasing topline results by mid-2028.
Advertisement

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data - Slideshow (NASDAQ:RCKT) 2026-10-07

https://seekingalpha.com/article/4952413-rocket-pharmaceuticals-inc-rckt-discusses-danon-disease-program-update-with-focus-on-rp-a501
Rocket Pharmaceuticals, Inc. (RCKT) presented a slide deck discussing updates on its Danon Disease program. The presentation focused on the RP-A501 pivotal trial and preliminary clinical data related to the treatment. This information was released in conjunction with a company event.

Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset

https://www.tradingview.com/news/marketbeat:98857f77a094b:0-rocket-pharmaceuticals-details-rp-a501-pivotal-plan-after-safety-reset/
Rocket Pharmaceuticals (RCKT) has outlined updated clinical, regulatory, and commercial plans for its gene therapy RP-A501 for Danon disease. The company reported long-term Phase I findings and preliminary Phase II observations, along with an FDA-aligned pivotal study design targeting 12 male patients. Rocket has also revised its Phase II protocol after previous safety events, reducing the dose and adjusting the immunomodulatory regimen.

Rocket Pharmaceuticals, Inc. (RCKT) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/RCKT/
This article provides a detailed overview of Rocket Pharmaceuticals, Inc. (RCKT), a late-stage biotechnology company specializing in genetic therapies for rare diseases. It includes current stock performance, key financial metrics, a company overview outlining its pipeline for AAV and lentiviral programs, and recent news and analyst insights. The company is developing treatments for conditions like Danon disease and Fanconi Anemia.

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

https://natlawreview.com/press-releases/rocket-pharmaceuticals-secures-strategic-credit-facility-150-million
Rocket Pharmaceuticals (NASDAQ: RCKT) has secured a credit facility of up to $150 million from Hercules Capital (NYSE: HTGC) to bolster its financial position. The initial $35 million has been received, with additional tranches available upon meeting specified conditions and milestones, including a Danon clinical milestone. This funding will support the pivotal Phase 2 study of RP-A501 for Danon disease and advance its cardiovascular pipeline, extending Rocket's cash runway potentially into 2029.

Rocket Pharmaceuticals secures $150M credit facility

https://www.investing.com/news/company-news/rocket-pharmaceuticals-secures-150m-credit-facility-93CH-4935198
Rocket Pharmaceuticals Inc. has secured a credit facility worth up to $150 million from Hercules Capital Inc., receiving an initial $35 million. This financing is expected to extend the company's cash runway into the third quarter of 2028, with potential extensions into 2029. The funds will support the advancement of its cardiovascular pipeline, particularly the pivotal Phase 2 study for Danon disease.
Advertisement

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

https://www.financialcontent.com/article/bizwire-2026-10-6-rocket-pharmaceuticals-secures-strategic-credit-facility-for-up-to-150-million-from-hercules-capital
Rocket Pharmaceuticals has secured a credit facility of up to $150 million from Hercules Capital, enhancing its financial position to fund its pivotal Phase 2 study for Danon disease and advance its cardiovascular pipeline. The agreement provides $35 million immediately, with additional tranches available upon meeting specific conditions and milestones. This financing, combined with existing resources, is expected to extend Rocket's cash runway into the third quarter of 2028, with potential extensions into 2029.

FDA aligns on RP-A501: Rocket Pharmaceuticals stock sits 71.22 percent below target

https://www.ad-hoc-news.de/boerse/news/nebenwerte/fda-aligns-on-rp-a501-rocket-pharmaceuticals-stock-sits-71-22-percent/70215919
Rocket Pharmaceuticals (RCKT) stock is trading at EUR 2.32, significantly below Needham's USD 9.00 target, despite the FDA aligning with the continued enrollment and dosing for its RP-A501 Phase 2 trial for Danon disease. The company expects to complete dosing for the remaining nine patients by mid-2027, with primary assessment at 12 months. Analysts, including Needham and Chardan, maintain "Buy" ratings, highlighting a substantial valuation gap despite development risks, and Rocket plans a webinar on October 6, 2026, to provide further updates on the RP-A501 program.

Revenue per share of Rocket Pharmaceuticals, Inc. – HAN:9IP1

https://www.tradingview.com/symbols/HAN-9IP1/financials-statistics-and-ratios/revenue-per-share/
This article provides financial information for Rocket Pharmaceuticals, Inc. (HAN:9IP1), focusing on its revenue per share. It is listed on the Hannover Stock Exchange and indicates no trades occurred as the market is closed. The content is from TradingView, which aggregates market and reference data from sources like ICE Data Services and FactSet.

Rocket Pharmaceuticals Inc (RCKT) Stock Price Target & Forecast

https://www.tradingkey.com/markets/stocks/rckt/forecast
The article provides an analyst rating and forecast for Rocket Pharmaceuticals Inc (RCKT). Based on 14 analysts, the average price target for RCKT is $8.854, representing a potential upside of 241.20%. Analysts' consensus indicates a "Buy" trend, with specific forecasts for EPS and revenue also detailed.

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment

https://www.streetwisereports.com/article/2026/09/23/rocket-pharmaceuticals-advances-danon-disease-gene-therapy-trial-with-fda-alignment.html?m_t=2026_09_24_05_51_47
Rocket Pharmaceuticals (RCKT) has received FDA alignment to continue its Phase 2 trial of RP-A501 for Danon disease. The pivotal efficacy population will include 12 male patients treated at a recalibrated dose, with nine additional patients expected to be dosed by mid-2027. This FDA confirmation provides a clear path for the completion of the pivotal study for this rare genetic disorder.
Advertisement

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

https://www.insidermonkey.com/news/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-safety-concerns-1838893/
Rocket Pharmaceuticals (RCKT) has received FDA alignment to count three patients treated under a modified protocol toward its pivotal Phase 2 Danon disease trial, with nine more patients to be enrolled by mid-2027. While this clarifies the path forward and confirms 12-month co-primary endpoints, the company still needs to demonstrate longer-term safety and convincing efficacy data to address past concerns, including a patient death. The investment community awaits these crucial results to determine the therapy's approvability and commercial viability.

Rocket Pharmaceuticals stock holds focus on clinical milestones

https://www.ad-hoc-news.de/boerse/news/nebenwerte/rocket-pharmaceuticals-stock-holds-focus-on-clinical-milestones/70157072
Rocket Pharmaceuticals (RCKT) stock performance is heavily tied to its clinical development and cash position. The company reported $436 million in cash as of June 30, 2026, a significant decrease from $737 million at the end of 2025 due to $294 million in operating cash use in the first half of 2026. This highlights that liquidity and cash consumption are currently more critical indicators for investors than new revenue figures or pipeline potential, as clinical progress directly impacts the company's financial runway.

Rocket Pharma gets FDA alignment on Danon disease trial

https://www.investing.com/news/company-news/rocket-pharma-gets-fda-alignment-on-danon-disease-trial-93CH-4901318
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) announced that the FDA has aligned with its global pivotal Phase 2 trial design for RP-A501, a Danon disease treatment. The trial will include 12 male patients treated with a recalibrated dose, with the company expecting to complete dosing by mid-2027. The FDA confirmed continued enrollment after reviewing safety data, and the primary assessment will focus on myocardial LAMP2 protein expression and reduction in left ventricular mass index to support potential accelerated approval.

Have Insiders Sold Rocket Pharmaceuticals Shares Recently?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rckt/rocket-pharmaceuticals/news/have-insiders-sold-rocket-pharmaceuticals-shares-recently-1
Rocket Pharmaceuticals (NASDAQ: RCKT) recently saw its General Counsel, Martin Wilson, sell US$256k worth of shares, representing an 11% reduction in his holding. While this was the largest insider sale in the past year, insiders have sold more shares than they have bought overall. Despite insiders owning about 4.0% of the company, Simply Wall St suggests caution due to the selling activity and advises investors to consider potential risks.

Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes

https://www.stocktitan.net/sec-filings/RCKT/144-rocket-pharmaceuticals-inc-sec-filing-f954776ea430.html
Former Rocket Pharmaceuticals officer John Militello has filed a Rule 144 notice to sell 6,897 shares of RCKT common stock. These shares stem from recently vested restricted stock awards and the sale includes shares designated to cover tax obligations associated with the equity award distribution. The filing also details Militello's prior stock sales within the last three months.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement